Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Major contract win

16 May 2014 12:25

RNS Number : 3595H
Venn Life Sciences Holdings PLC
16 May 2014
 



Venn Life Sciences Holdings Plc

("Venn" or the "Company")

 

Major contract win

 

Venn Life Sciences Signs Master Service Agreement for Multi-Country Study

Value is in excess of €3m covering 8 countries in Europe & North America over 18 months

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the securing of a multi-country multi-million euro clinical trials management agreement with a major European biotechnology company.

 

This multi-site agreement will run for over a year and a half, covering seven European countries as well as a number of US sites and is valued in excess of €3m. The clinical trial management programme is for an orphan drug in a rare acute disease area and is proceeding this month.

 

Over the past year Venn has increased its geographic footprint in Europe with new offices in the UK and Germany. Business development has been focused on key growth areas of drug and device development and on winning similar studies across Europe, with a solid pipeline of work for 2014 and 2015 now secured. Studies in rare diseases have increased significantly in recent years and Venn has invested in ensuring they have the critical multi-site agile service capabilities essential to conduct and manage trials efficiently in this sector.

 

Commenting, Venn CEO, Tony Richardson, said:

"We are hearing from many of our clients - in the key pharmaceutical, biotechnology and medical device sectors - of a growing need for a much more agile multi-country clinical trial management capability, especially in the still complex greater European region. Venn has invested heavily in 2013 in preparing the business for a step change in the size and complexity of contracts undertaken. This contract win, and our current pipeline, represent a significant endorsement of our investment strategy since IPO. We have now moved our business focus from small single country projects to larger multicentred projects and we expect to cement this progress with additional project wins in the coming months."

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla McGuinness, Marketing Manager

Tel: +33 (0)1 30 82 67 07

Zeus Capital (Nominated Adviser and Broker)

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: 0161 831 1512

Dominic Wilson (Institutional Sales)

Tel: 020 7533 7727

Walbrook PR Ltd

Tel: 020 7933 8787 or venn@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management solutions and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK and Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - innoVenn - focused primarily on breakthrough development opportunities in Skin Science.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTBBGDUSDBBGSL
Date   Source Headline
10th May 20197:00 amRNSPreliminary Final Results
1st May 201911:00 amRNSChanges to interests of a significant shareholder
1st May 201911:00 amRNSIntegumen Debt Conversion
8th Apr 20197:00 amRNSFinancing Update
26th Mar 20197:00 amRNSChange of Adviser
21st Jan 20194:40 pmRNSSecond Price Monitoring Extn
21st Jan 20194:35 pmRNSPrice Monitoring Extension
18th Jan 20197:00 amRNSPartnership Announcement
24th Dec 201812:36 pmRNSPrice Monitoring Extension
21st Dec 20184:29 pmRNSDirector/PDMR Shareholding
20th Dec 20185:04 pmRNSHolding(s) in Company
11th Dec 20187:00 amRNSStrategic Collaboration Agreement and Financing
8th Nov 201810:40 amRNSTrading Update and Change of Adviser
5th Oct 20183:36 pmRNSHolding(s) in Company
25th Sep 20187:00 amRNSHalf-year Report
17th Sep 20187:00 amRNSFirst laboratory-grown human-skin test service
30th Jul 201811:27 amRNSHolding(s) in Company
26th Jul 20185:01 pmRNSHolding(s) in Company
26th Jul 20185:00 pmRNSHolding(s) in Company
26th Jul 20183:40 pmRNSHolding(s) in Company
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
24th Jul 20188:00 amRNSEnterprise Securities Market Notice
20th Jul 20183:22 pmRNSResult of General Meeting
4th Jul 20187:00 amRNSPlacing & Subscription to raise up to £0.65m
28th Jun 201811:47 amRNSResult of AGM
6th Jun 20184:55 pmRNSNotice of AGM & Posting of Annual Report&Accounts
17th May 20187:00 amRNSFinal Results
23rd Apr 20187:00 amRNSNotice of Results
21st Mar 20187:00 amRNSDirectorate Change
15th Feb 20187:00 amRNSTrading Statement
25th Jan 20187:00 amRNSChange of Adviser
23rd Jan 20187:00 amRNSAcquisition of Minority Interest
14th Sep 20175:19 pmRNSGrant of Stock Options
12th Sep 20177:00 amRNSHalf-year Report
25th Jul 20177:00 amRNSSenior Management Appointment
20th Jul 20177:00 amRNSHalf year end update
26th Apr 20176:01 pmRNSResult of AGM
25th Apr 20173:13 pmRNSProposed amendment to AGM resolution
5th Apr 20177:00 amRNSIntegumen IPO
4th Apr 20177:00 amRNSEnterprise Securities Market Notice
31st Mar 201711:26 amRNSAnnual Financial Report & Notice of AGM
29th Mar 20171:57 pmRNSIssue of Equity
22nd Mar 20177:00 amRNSFinal Results
3rd Mar 20177:00 amRNSYear End Update
18th Nov 20167:00 amRNSCompletion of Sale
10th Nov 20165:51 pmRNSREPLACEMENT - Contract win
8th Nov 20167:00 amRNSContract win
2nd Nov 20167:03 amRNSDirector/PDMR Shareholding
27th Oct 20167:00 amRNSSale of Innovenn UK Limited and Result of GM
4th Oct 20167:00 amRNSSale of Innovenn & Notice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.